drugset / Trial / NCT00306475
Does The Addition Of Divalproex Sodium ER To An Atypical Antipsychotic Drug (APD) Improve Cognition And Psychopathology In Outpatients With Schizophrenia (SCH) Or Schizoaffective Disorder (SAD)?
Phase 4
Completed
60 enrolled
Northwestern University
Abbott · collabNational Alliance for Research on Schizophrenia and Depression · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The major objective of this proposal is to test the hypothesis that the addition of divalproex sodium to an atypical antipsychotic drug other than clozapine will significantly improve: a) cognition; and b) psychopathology (positive, negative, and mood symptoms) in a double-blind, randomized trial of 6 weeks duration in patients with schizophrenia or schizoaffective disorder.
Timeline
- Start
- 2006-03
- Primary completion
- 2008-04
- Completion
- 2008-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Divalproex Sodium Extended-Release Tablets | Unknown | 1000 mg | — |